FDA strengthens regulations for surgical mesh used in transvaginal procedures

February 21, 2018

The U.S. Food and Drug Administration (FDA) is enforcing stricter regulations for surgical mesh products used in transvaginal procedures to repair pelvic organ prolapse (POP). The products are being reclassified from moderate risk (class II) to high risk (class III) when used transvaginally. 

The stricter regulations do not apply to surgical mesh for other indications, such as stress urinary incontinence or abdominal repair of POP.

The FDA now requires all manufacturers of mesh products to submit data that supports the effectiveness and safety of the devices. Manufacturers with products currently on the market will have 30 months to comply with the new requirements.

According to the FDA, a significant increase has occurred over the past several years in the number of reported adverse events associated with the use of surgical mesh for transvaginal POP repair, such as severe pelvic pain, infection, and organ perforation. 

In 2011, an advisory panel of experts recommended that more data was needed to establish the safety of the device. The FDA has since taken several actions to warn doctors and patients about the use of surgical mesh for transvaginal POP repair.

Read full articles on this news item on the FDA website and Wall Street Journal online.

Previous Article
How secure is your patient portal?

Recently the National Cybersecurity and Communications Integration Center issued an alert concerning SSL 3....

Next Article
TMLT Dedicates $15 Million to Trust Rewards Program for 2015

Texas Medical Liability Trust (TMLT) announced today that the Board of Governors voted to dedicate $15 mill...

Telemedicine in Texas: Risks, Rewards, and Where We Go Next [CME webinar]

Learn More